At the 2018 ASH meeting, Yasuda et al. reported that among 149 adult BCP-ALL patients treated with JALSG ALL202-O protocol, ZNF384 fusions were associated with better DFS than B-others and should be classified as favorable-risk group (9). The gene discussed is ZNF384; the disease is acute lymphoblastic leukemia.